Initially there was no specific way to reverse the anticoagulant effect of dabigatran I mean um um well well like you know um uh I mean dabigatran dabigatran dabigatran dabigatran dabigatran dabigatran dabigatran dabigatran dabigatran dabigatran in the event so uh okay um well okay uh well well okay of a major bleeding event, unlike for warfarin, but a dabigatran antidote (idarucizumab) was approved by the FDA in 2015.